[ad_1]
Today, Tuesday, the U.S. Food and Drug Administration agreed to grant an emergency use license for the Eli Lily drug, which is used to treat mild and moderate cases of people with the emerging corona virus (Covid-19 ).
The US channel (Al-Hurra) said the authority authorized the federal government to distribute the drug (bamlanivimab) to U.S. health departments, pointing out that this drug cannot be administered to difficult cases of Corona patients, which must be placed on a respirator.
Last month, the United States allocated 300,000 doses of the investigational drug and also paid the company $ 375 million to produce this drug, and under this license, people 12 years or older and weighing 40 kilograms. they will be able to get this drug.
And the Donald Trump government had already announced the purchase of 300,000 doses of this drug called Bamlanivimab at the end of last October.
It is a recommended antibody treatment for patients who have recently been diagnosed with emerging coronavirus and who have not been hospitalized or need oxygen, because it has not shown any benefit in this type of person.
It has shown benefits in people over the age of 65 and in those suffering from chronic diseases, who are the groups most affected by the epidemic.
“As the evaluation of the safety and efficacy of this experimental treatment continues, clinical trials have shown that pamlanifemab reduces hospital admissions due to (Covid-19) and emergency visits for high-risk patients,” he said. the FDA in a statement.
The American pharmaceutical company must deliver 300,000 doses to the government, purchased for 375 million dollars, within two months, according to what was announced last October after the signing of the contract between the two parties.
Trump said during his recovery nearly a month ago that Eli Lilly was one of the most promising treatments for dealing with the epidemic.
Then the outgoing president was treated with antibody therapy (Regeneron), which also required approval for emergency use, and the antiviral remdesivir, manufactured by Gilad Sciences, which recently obtained definitive permission to treat the COVID-19 patients).
This emergency use approval comes on the same day that the United States surpassed 10 million cases of the emerging coronavirus and has already recorded more than 238,000 deaths, more than any other country in the world.
Interestingly, the American pharmaceutical company Pfizer has announced that its vaccine trials for (Covid-19) have shown efficacy of over 90%.
.
[ad_2]
Source link
